| Exhibit | Description | ||||
| 99.1 | Press release dated July 31, 2025 | ||||
|
SEQUANS COMMUNICATIONS S.A.
(Registrant)
|
||||||||||||||
| Date: July 31, 2025 | By: | /s/ Deborah Choate | ||||||||||||
| Deborah Choate | ||||||||||||||
| Chief Financial Officer | ||||||||||||||
![]() |
NEWS
|
||||
| (in US$ millions, except share and per share data) | Q2 2025 (1) |
Q1 2025 (1) |
Q2 2024 | ||||||||
| Revenue | $8.1 | $8.1 | $9.7 | ||||||||
| Gross profit | $5.2 | $5.2 | $8.1 | ||||||||
| Gross margin (%) | 64.4 | % | 64.5 | % | 84.0 | % | |||||
| Operating income (loss) | ($8.7) | ($6.8) | ($3.7) | ||||||||
| Net profit (loss) | ($9.1) | ($7.3) | ($0.6) | ||||||||
| Diluted income (loss) per ADS | ($0.36) | ($0.29) | ($0.02) | ||||||||
Non-IFRS diluted income (loss) per ADS (2) |
($0.32) | ($0.24) | ($0.23) | ||||||||
| Weighted average number of diluted ADS (IFRS) | 25,406,045 | 25,156,570 | 24,765,063 | ||||||||
| Weighted average number of diluted ADS (Non-IFRS) | 25,406,045 | 25,156,570 | 24,765,063 | ||||||||
| (1) Final results are subject to finalization of the allocation of the ACP acquisition purchase price | |||||||||||
| (2) See Use of Non-IFRS/non-GAAP Financial Measures disclosure on page 3. IFRS Net Loss in Q2 2024 includes significant non-cash interest expense, debt amendment and change in value of embedded derivative that are excluded from Non-IFRS measures | |||||||||||
| (*) Bitcoin KPIs will be presented beginning with the results of the third quarter of 2025 | |||||||||||
| Three months ended | ||||||||||||||||||||||||||
| (in thousands of US$, except share and per share amounts) |
June 30,
2025 (1)
|
March 31, 2025 (1) |
June 30, 2024 | |||||||||||||||||||||||
| Revenue: | ||||||||||||||||||||||||||
| Product revenue | $ | 3,872 | $ | 3,509 | $ | 2,435 | ||||||||||||||||||||
| License and services revenue | 4,270 | 4,545 | 7,240 | |||||||||||||||||||||||
| Total revenue | 8,142 | 8,054 | 9,675 | |||||||||||||||||||||||
| Cost of revenue | (2,900) | (2,863) | (1,547) | |||||||||||||||||||||||
| Gross profit | 5,242 | 5,191 | 8,128 | |||||||||||||||||||||||
| Operating income (expenses) : | ||||||||||||||||||||||||||
| Research and development expense | (8,779) | (7,227) | (5,789) | |||||||||||||||||||||||
| Sales and marketing expense | (2,176) | (2,337) | (3,131) | |||||||||||||||||||||||
| General and administrative expense | (3,019) | (2,451) | (2,916) | |||||||||||||||||||||||
| Total operating income (expenses) | (13,974) | (12,015) | (11,836) | |||||||||||||||||||||||
| Operating profit (loss) | (8,732) | (6,824) | (3,708) | |||||||||||||||||||||||
| Financial income (expense): | ||||||||||||||||||||||||||
| Interest income (expense), net | 250 | 368 | (10,806) | |||||||||||||||||||||||
| Change in fair value of convertible debt derivative | — | — | 39 | |||||||||||||||||||||||
| Impact of debt amendment | — | — | 13,952 | |||||||||||||||||||||||
| Foreign exchange gain (loss) | (476) | (517) | 90 | |||||||||||||||||||||||
| Profit (Loss) before income taxes | (8,958) | (6,973) | (433) | |||||||||||||||||||||||
| Income tax expense | (154) | (281) | (146) | |||||||||||||||||||||||
| Profit (Loss) | $ | (9,112) | $ | (7,254) | $ | (579) | ||||||||||||||||||||
| Attributable to: | ||||||||||||||||||||||||||
| Shareholders of the parent | (9,112) | (7,254) | (579) | |||||||||||||||||||||||
| Minority interests | — | — | — | |||||||||||||||||||||||
| Basic income (loss) per ADS | ($0.36) | ($0.29) | ($0.02) | |||||||||||||||||||||||
| Diluted income (loss) per ADS | ($0.36) | ($0.29) | ($0.02) | |||||||||||||||||||||||
| Weighted average number of ADS used for computing: | ||||||||||||||||||||||||||
| — Basic | 25,406,045 | 25,156,570 | 24,765,063 | |||||||||||||||||||||||
| — Diluted | 25,406,045 | 25,156,570 | 24,765,063 | |||||||||||||||||||||||
| (1) Final results are subject to finalization of the allocation of the ACP acquisition purchase price. | ||||||||||||||||||||||||||
| Six months ended June 30, | |||||||||||||||||
| (in thousands of US$, except share and per share amounts) | 2025 (1) |
2024 | |||||||||||||||
| Revenue: | |||||||||||||||||
| Product revenue | $ | 7,381 | $ | 4,903 | |||||||||||||
| License and services revenue | 8,815 | 10,799 | |||||||||||||||
| Total revenue | 16,196 | 15,702 | |||||||||||||||
| Cost of revenue | (5,763) | (3,720) | |||||||||||||||
| Gross profit | 10,433 | 11,982 | |||||||||||||||
| Operating income (expenses) : | |||||||||||||||||
| Research and development expense | (16,006) | (12,402) | |||||||||||||||
| Sales and marketing expense | (4,513) | (6,003) | |||||||||||||||
| General and administrative expense | (5,470) | (5,818) | |||||||||||||||
| Total operating income (expenses) | (25,989) | (24,223) | |||||||||||||||
| Operating profit (loss) | (15,556) | (12,241) | |||||||||||||||
| Financial income (expense): | |||||||||||||||||
| Interest income (expense), net | 618 | (14,124) | |||||||||||||||
| Change in fair value of convertible debt derivative | — | 3 | |||||||||||||||
| Impact of debt amendment | — | 13,952 | |||||||||||||||
| Foreign exchange gain (loss) | (993) | 354 | |||||||||||||||
| Profit (Loss) before income taxes | (15,931) | (12,056) | |||||||||||||||
| Income tax expense | (435) | (313) | |||||||||||||||
| Profit (Loss) | $ | (16,366) | $ | (12,369) | |||||||||||||
| Attributable to: | |||||||||||||||||
| Shareholders of the parent | (16,366) | (12,369) | |||||||||||||||
| Minority interests | — | — | |||||||||||||||
| Basic income (loss) per ADS | ($0.65) | ($0.50) | |||||||||||||||
| Diluted income (loss) per ADS | ($0.65) | ($0.50) | |||||||||||||||
| Weighted average number of ADS used for computing: | |||||||||||||||||
| — Basic | 25,282,261 | 24,705,875 | |||||||||||||||
| — Diluted | 25,282,261 | 24,705,875 | |||||||||||||||
| (1) Final results are subject to finalization of the allocation of the ACP acquisition purchase price. | |||||||||||||||||
| At June 30, | At Dec 31, | |||||||||||||
| (in thousands of US$) | 2025 (1) |
2024 |
||||||||||||
| ASSETS | ||||||||||||||
| Non-current assets | ||||||||||||||
| Property, plant and equipment | $ | 4,244 | $ | 4,308 | ||||||||||
| Intangible assets | 13,118 | 5,641 | ||||||||||||
| Deposits and other receivables | 3,653 | 3,246 | ||||||||||||
| Other non-current financial assets | 435 | 353 | ||||||||||||
| Total non-current assets | 21,450 | 13,548 | ||||||||||||
| Current assets | ||||||||||||||
| Inventories | 2,884 | 2,874 | ||||||||||||
| Trade receivables | 2,693 | 4,809 | ||||||||||||
| Contract assets | 13 | 122 | ||||||||||||
| Prepaid expenses | 1,755 | 1,410 | ||||||||||||
| Other receivables | 13,081 | 17,492 | ||||||||||||
| Research tax credit receivable | 4,815 | 4,184 | ||||||||||||
| Short-term deposits | 23,000 | 53,000 | ||||||||||||
| Cash and cash equivalents | 18,600 | 9,093 | ||||||||||||
| Total current assets | 66,841 | 92,984 | ||||||||||||
| Total assets | $ | 88,291 | $ | 106,532 | ||||||||||
| EQUITY AND LIABILITIES | ||||||||||||||
| Equity | ||||||||||||||
| Issued capital, euro 0.01 nominal value, 255,176,342 shares authorized, issued and outstanding at June 30, 2025 (251,408,922 shares at December 31, 2024) | $ | 2,974 | $ | 2,934 | ||||||||||
| Share premium | 14,473 | 14,512 | ||||||||||||
| Other capital reserves | 76,397 | 74,504 | ||||||||||||
| Accumulated deficit | (52,161) | (35,795) | ||||||||||||
| Other components of equity | (215) | (796) | ||||||||||||
| Total equity | 41,468 | 55,359 | ||||||||||||
| Non-current liabilities | ||||||||||||||
| Government loan | — | 616 | ||||||||||||
| Government research financing | 4,723 | 5,669 | ||||||||||||
| Lease liabilities | — | 333 | ||||||||||||
| Trade payables and other non-current liabilities | 667 | — | ||||||||||||
| Provisions | 2,147 | 1,400 | ||||||||||||
| Deferred tax liabilities | 190 | 173 | ||||||||||||
| Contract liabilities | 2,641 | 809 | ||||||||||||
| Total non-current liabilities | 10,368 | 9,000 | ||||||||||||
| Current liabilities | ||||||||||||||
| Trade payables | 9,812 | 6,106 | ||||||||||||
| Interest-bearing receivables financing | — | 3,742 | ||||||||||||
| Lease liabilities | 1,126 | 1,439 | ||||||||||||
| Government loan | 1,837 | 1,802 | ||||||||||||
| Government research financing | 3,250 | 4,062 | ||||||||||||
| Contract liabilities | 5,513 | 11,021 | ||||||||||||
| Income tax liabilities - Parent | 3,761 | 2,827 | ||||||||||||
| Other current liabilities and provisions | 11,156 | 11,174 | ||||||||||||
| Total current liabilities | 36,455 | 42,173 | ||||||||||||
| Total equity and liabilities | $ | 88,291 | $ | 106,532 | ||||||||||
| (1) Final results are subject to finalization of the allocation of the ACP acquisition purchase price. | ||||||||||||||
| Six months ended June 30, | ||||||||||||||||||||
| (in thousands of US$) | 2025 (1) |
2024 | ||||||||||||||||||
| Operating activities | ||||||||||||||||||||
| Loss before income taxes | $ | (15,931) | $ | (12,056) | ||||||||||||||||
| Non-cash adjustment to reconcile income before tax to net cash from (used in) operating activities | ||||||||||||||||||||
| Depreciation and impairment of property, plant and equipment | 1,418 | 1,670 | ||||||||||||||||||
| Amortization and impairment of intangible assets | 1,960 | 2,748 | ||||||||||||||||||
| Share-based payment expense | 1,893 | 2,964 | ||||||||||||||||||
| Decrease in provision | (92) | (219) | ||||||||||||||||||
| Interest (income) expense, net | (620) | 14,124 | ||||||||||||||||||
| Change in the fair value of convertible debt embedded derivative | — | (3) | ||||||||||||||||||
| Convertible debt amendment | — | (13,952) | ||||||||||||||||||
| Foreign exchange loss (gain) | (525) | 216 | ||||||||||||||||||
| Loss on disposal of intangible and tangible assets | 12 | — | ||||||||||||||||||
| Working capital adjustments | ||||||||||||||||||||
| Decrease in trade receivables and other receivables | 3,066 | 5,209 | ||||||||||||||||||
| Decrease in inventories | 48 | 1,812 | ||||||||||||||||||
| Increase in research tax credit receivable | (509) | (987) | ||||||||||||||||||
| Increase in trade payables and other liabilities | 1,790 | 792 | ||||||||||||||||||
| Increase (Decrease) in contract liabilities | (5,146) | 5,102 | ||||||||||||||||||
| Increase in government grant advances | 2,044 | 3,112 | ||||||||||||||||||
| Income tax paid | (586) | (560) | ||||||||||||||||||
| Net cash flow from (used in) operating activities | (11,178) | 9,972 | ||||||||||||||||||
| Investing activities | ||||||||||||||||||||
| Purchase of intangible assets and property, plant and equipment | (1,109) | (1,200) | ||||||||||||||||||
| Capitalized development expenditures | — | (14,851) | ||||||||||||||||||
| Investment in ACP Advanced Circuit Pursuit, net of cash acquired | (3,586) | — | ||||||||||||||||||
| Sale (Purchase) of financial assets | (151) | 60 | ||||||||||||||||||
| Decrease of short-term deposit | 30,000 | — | ||||||||||||||||||
| Interest received | 990 | 27 | ||||||||||||||||||
| Net cash flow from (used in) investing activities | 26,144 | (15,964) | ||||||||||||||||||
| Financing activities | ||||||||||||||||||||
| Proceeds (repayment of) from interest-bearing receivables financing | (3,742) | 577 | ||||||||||||||||||
| Proceeds from related party loans | — | 14,000 | ||||||||||||||||||
| Proceeds from interest-bearing research project financing | 1,129 | 934 | ||||||||||||||||||
| Payment of lease liabilities | (749) | (753) | ||||||||||||||||||
| Repayment of government loans | (678) | (679) | ||||||||||||||||||
| Repayment of loans | (420) | — | ||||||||||||||||||
| Repayment of interest-bearing research project financing | (395) | (266) | ||||||||||||||||||
| Interest paid | (637) | (412) | ||||||||||||||||||
| Net cash flows from (used in) financing activities | (5,492) | 13,401 | ||||||||||||||||||
| Net increase (decrease) in cash and cash equivalents | 9,474 | 7,409 | ||||||||||||||||||
| Net foreign exchange difference | 33 | (6) | ||||||||||||||||||
| Cash and cash equivalents at January 1 | 9,093 | 5,705 | ||||||||||||||||||
| Cash and cash equivalents at end of the period | 18,600 | 13,108 | ||||||||||||||||||
| (1) Final results are subject to finalization of the allocation of the ACP acquisition purchase price. | ||||||||||||||||||||
| (in thousands of US$, except share and per share amounts) | Three months ended | ||||||||||||||||||||||
|
June 30,
2025 (3)
|
March 31, 2025 | June 30, 2024 | |||||||||||||||||||||
| IFRS profit (loss) as reported | $ | (9,112) | $ | (7,254) | $ | (579) | |||||||||||||||||
| Add back | |||||||||||||||||||||||
Non-cash stock-based compensation expense according to IFRS 2 (1) |
879 | 1,014 | 1,847 | ||||||||||||||||||||
| Non-cash change in the fair value of convertible debt embedded derivative | — | — | (39) | ||||||||||||||||||||
Non-cash interest on convertible debt and other financing (2) |
108 | 111 | 6,972 | ||||||||||||||||||||
| Non-IFRS profit (loss) adjusted | $ | (8,125) | $ | (6,129) | $ | (5,751) | |||||||||||||||||
| IFRS basic profit (loss) per ADS as reported | ($0.36) | ($0.29) | ($0.02) | ||||||||||||||||||||
| Add back | |||||||||||||||||||||||
Non-cash stock-based compensation expense according to IFRS 2 (1) |
$0.03 | $0.04 | $0.07 | ||||||||||||||||||||
| Non-cash change in the fair value of convertible debt embedded derivative | $0.00 | $0.00 | $0.00 | ||||||||||||||||||||
Non-cash interest on convertible debt and other financing (2) |
$0.01 | $0.01 | $0.28 | ||||||||||||||||||||
| Non-IFRS basic profit (loss) per ADS | ($0.32) | ($0.24) | ($0.23) | ||||||||||||||||||||
| IFRS diluted profit (loss) per ADS | ($0.36) | ($0.29) | ($0.02) | ||||||||||||||||||||
| Add back | |||||||||||||||||||||||
Non-cash stock-based compensation expense according to IFRS 2 (1) |
$0.03 | $0.04 | $0.07 | ||||||||||||||||||||
| Non-cash change in the fair value of convertible debt embedded derivative | $0.00 | $0.00 | $0.00 | ||||||||||||||||||||
Non-cash interest on convertible debt and other financing (2) |
$0.01 | $0.01 | $0.28 | ||||||||||||||||||||
| Non-IFRS diluted profit (loss) per ADS | ($0.32) | ($0.24) | ($0.23) | ||||||||||||||||||||
| (1) Included in the IFRS profit (loss) as follows: | |||||||||||||||||||||||
| Cost of product revenue | $ | 13 | $ | 16 | $ | 27 | |||||||||||||||||
| Research and development | 181 | 205 | 509 | ||||||||||||||||||||
| Sales and marketing | 191 | 223 | 435 | ||||||||||||||||||||
| General and administrative | 494 | 570 | 876 | ||||||||||||||||||||
| (2) Related to the difference between contractual and effective interest rates | |||||||||||||||||||||||
| (3) Final results are subject to finalization of the allocation of the ACP acquisition purchase price | |||||||||||||||||||||||
| (in thousands of US$, except share and per share amounts) | Six months ended June 30, | ||||||||||||||||
2025 (3) |
2024 | ||||||||||||||||
| IFRS profit (loss) as reported | $ | (16,366) | $ | (12,369) | |||||||||||||
| Add back | |||||||||||||||||
Non-cash stock-based compensation expense according to IFRS 2 (1) |
1,893 | 2,964 | |||||||||||||||
| Non-cash change in the fair value of convertible debt embedded derivative | — | (3) | |||||||||||||||
Non-cash interest on convertible debt and other financing (2) |
218 | 8,805 | |||||||||||||||
| Non-cash impact of convertible debt amendment | — | (13,952) | |||||||||||||||
| Non-IFRS profit (loss) adjusted | $ | (14,255) | $ | (14,555) | |||||||||||||
| IFRS basic profit (loss) per ADS as reported | ($0.65) | ($0.50) | |||||||||||||||
| Add back | |||||||||||||||||
Non-cash stock-based compensation expense according to IFRS 2 (1) |
$0.07 | $0.12 | |||||||||||||||
| Non-cash change in the fair value of convertible debt embedded derivative | $0.00 | $0.00 | |||||||||||||||
Non-cash interest on convertible debt and other financing (2) |
$0.01 | $0.35 | |||||||||||||||
| Non-cash impact of convertible debt amendment | $0.00 | ($0.56) | |||||||||||||||
| Non-IFRS basic profit (loss) per ADS | ($0.56) | ($0.59) | |||||||||||||||
| IFRS diluted profit (loss) per ADS | ($0.65) | ($0.50) | |||||||||||||||
| Add back | |||||||||||||||||
Non-cash stock-based compensation expense according to IFRS 2 (1) |
$0.07 | $0.12 | |||||||||||||||
| Non-cash change in the fair value of convertible debt embedded derivative | $0.00 | $0.00 | |||||||||||||||
Non-cash interest on convertible debt and other financing (2) |
$0.01 | $0.35 | |||||||||||||||
| Non-cash impact of convertible debt amendment | $0.00 | ($0.56) | |||||||||||||||
| Non-IFRS diluted profit (loss) per ADS | ($0.56) | ($0.59) | |||||||||||||||
| (1) Included in the IFRS profit (loss) as follows: | |||||||||||||||||
| Cost of product revenue | $ | 29 | $ | 44 | |||||||||||||
| Research and development | 386 | 827 | |||||||||||||||
| Sales and marketing | 414 | 678 | |||||||||||||||
| General and administrative | 1,064 | 1,415 | |||||||||||||||
| (2) Related to the difference between contractual and effective interest rates | |||||||||||||||||
| (3) Final results are subject to finalization of the allocation of the ACP acquisition purchase price | |||||||||||||||||